argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
901.17
-14.80 (-1.62%)
At close: Dec 5, 2025, 4:00 PM EST
902.00
+0.83 (0.09%)
After-hours: Dec 5, 2025, 7:19 PM EST
argenx SE Revenue
argenx SE had revenue of $1.15B in the quarter ending September 30, 2025, with 95.51% growth. This brings the company's revenue in the last twelve months to $3.68B, up 92.98% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
$3.68B
Revenue Growth
+92.98%
P/S Ratio
14.90
Revenue / Employee
$2,303,490
Employees
1,599
Market Cap
54.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
| Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
| Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
| Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
| Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ARGX News
- 9 days ago - argenx: Sights Set On $1,000 - Seeking Alpha
- 19 days ago - PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors - Seeking Alpha
- 4 weeks ago - Baron International Growth Fund Q3 2025 Contributors And Detractors - Seeking Alpha
- 4 weeks ago - Biotech is back. Here's why these rallying stocks belong in your portfolio now. - Market Watch
- 5 weeks ago - argenx SE (ARGX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - argenx Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients - GlobeNewsWire
- 5 weeks ago - Baron Health Care Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha